SMC accepts treatment for relapsing-remitting multiple sclerosis
Ofatumumab is accepted for restricted use within NHS Scotland.
Multiple Sclerosis Room
In this room you can find updates and expert discussions about MS.
Ozanimod not recommended for relapsing–remitting multiple sclerosis
Ozanimod's effect on the progression of disability is unclear and cost-effectiveness estimates are higher than what NICE normally considers an acceptable use of NHS resources, according to final guidance.
SMC accepts two neurology treatments
Medicines indicated in multiple sclerosis and CLN2 disease within NHS Scotland.
MS clinics: view from the frontline
Thoughts and local perspective on applying the latest ABN guidance on DMTs use in MS
